Identification and mechanistic studies of a novel ubiquitin E1 inhibitor
- PMID: 22274912
- PMCID: PMC3339042
- DOI: 10.1177/1087057111433843
Identification and mechanistic studies of a novel ubiquitin E1 inhibitor
Abstract
Protein degradation via the ubiquitin-proteasome pathway is important for a diverse number of cellular processes ranging from cell signaling to development. Disruption of the ubiquitin pathway occurs in a variety of human diseases, including several cancers and neurological disorders. Excessive proteolysis of tumor suppressor proteins, such as p27, occurs in numerous aggressive human tumors. To discover small-molecule inhibitors that potentially prevent p27 degradation, we developed a series of screening assays, including a cell-based screen of a small-molecule compound library and two novel nucleotide exchange assays. Several small-molecule inhibitors, including NSC624206, were identified and subsequently verified to prevent p27 ubiquitination in vitro. The mechanism of NSC624206 inhibition of p27 ubiquitination was further unraveled using the nucleotide exchange assays and shown to be due to antagonizing ubiquitin activating enzyme (E1). We determined that NSC624206 and PYR-41, a recently reported inhibitor of ubiquitin E1, specifically block ubiquitin-thioester formation but have no effect on ubiquitin adenylation. These studies reveal a novel E1 inhibitor that targets a specific step of the E1 activation reaction. NSC624206 could, therefore, be potentially useful for the control of excessive ubiquitin-mediated proteolysis in vivo.
Conflict of interest statement
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures








Similar articles
-
Largazole and its derivatives selectively inhibit ubiquitin activating enzyme (e1).PLoS One. 2012;7(1):e29208. doi: 10.1371/journal.pone.0029208. Epub 2012 Jan 18. PLoS One. 2012. PMID: 22279528 Free PMC article.
-
Domain alternation and active site remodeling are conserved structural features of ubiquitin E1.J Biol Chem. 2017 Jul 21;292(29):12089-12099. doi: 10.1074/jbc.M117.787622. Epub 2017 Jun 1. J Biol Chem. 2017. PMID: 28572513 Free PMC article.
-
The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma.Blood. 2010 Mar 18;115(11):2251-9. doi: 10.1182/blood-2009-07-231191. Epub 2010 Jan 14. Blood. 2010. PMID: 20075161 Free PMC article.
-
E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.Curr Cancer Drug Targets. 2016;16(2):130-5. doi: 10.2174/1568009616666151112122336. Curr Cancer Drug Targets. 2016. PMID: 26560119 Review.
-
[The degradation of p27 and cancer].Nihon Rinsho. 2005 Nov;63(11):2047-56. Nihon Rinsho. 2005. PMID: 16277271 Review. Japanese.
Cited by
-
Exploiting the potential of the ubiquitin-proteasome system in overcoming tyrosine kinase inhibitor resistance in chronic myeloid leukemia.Genes Dis. 2023 Oct 26;11(5):101150. doi: 10.1016/j.gendis.2023.101150. eCollection 2024 Sep. Genes Dis. 2023. PMID: 38947742 Free PMC article. Review.
-
Elevated post-ischemic ubiquitination results from suppression of deubiquitinase activity and not proteasome inhibition.Cell Mol Life Sci. 2021 Mar;78(5):2169-2183. doi: 10.1007/s00018-020-03625-5. Epub 2020 Sep 5. Cell Mol Life Sci. 2021. PMID: 32889561 Free PMC article.
-
Inhibition of the Ubiquitin-Activating Enzyme UBA1 Suppresses Diet-Induced Atherosclerosis in Apolipoprotein E-Knockout Mice.J Immunol Res. 2020 Mar 20;2020:7812709. doi: 10.1155/2020/7812709. eCollection 2020. J Immunol Res. 2020. PMID: 32258175 Free PMC article.
-
Unexpected requirement for a binding partner of the syntaxin family in phagocytosis by murine testicular Sertoli cells.Cell Death Differ. 2016 May;23(5):787-800. doi: 10.1038/cdd.2015.139. Epub 2015 Oct 23. Cell Death Differ. 2016. PMID: 26494466 Free PMC article.
-
Novel strategies to target the ubiquitin proteasome system in multiple myeloma.Oncotarget. 2016 Feb 9;7(6):6521-37. doi: 10.18632/oncotarget.6658. Oncotarget. 2016. PMID: 26695547 Free PMC article. Review.
References
-
- Hershko A, Ciechanover A. Mechanisms of Intracellular Protein Breakdown. Annu Rev Biochem. 1982;51:335–364. - PubMed
-
- Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy. Oncologist. 2003;8:508–513. - PubMed
-
- San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, et al. Bortezomib Plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. N Engl J Med. 2008;359:906–917. - PubMed
-
- Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M. Role of the Ubiquitin-Proteasome Pathway in Regulating Abundance of the Cyclin-Dependent Kinase Inhibitor p27. Science. 1995;269:682–685. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials